Pluristyx and BioLamina Join Forces to Enhance Stem Cell Therapy Development
The collaboration aims to streamline iPSC-based therapy development by integrating advanced cell engineering with specialized culture matrices.
Pluristyx and BioLamina have announced a strategic co-development and co-marketing partnership aimed at simplifying and accelerating the development of induced pluripotent stem cell (iPSC)-based therapies.
The collaboration is designed to provide researchers and developers with a streamlined, clinically relevant workflow by combining Pluristyx’s iPSC platform – including proprietary polyclonal derivation, iACT® immune cloaking, and FailSafe™ genetic engineering – with BioLamina’s chemically defined, animal origin-free Biolaminin® matrices.
The companies report that this partnership will enhance the consistency, scalability, and safety of iPSC-derived therapeutic products.
Get Regen Report in your inbox
Weekly updates on regenerative medicine news, trials, and regulatory moves.
According to Pluristyx, the focus will be on creating optimized, fully defined culture systems that ensure consistent cell quality and reproducibility. This is intended to support therapy developers as they advance their programs toward clinical applications.
“Our mission at Pluristyx is to empower the development of next-generation cell therapies. Partnering with BioLamina is a critical step toward that goal. Combining our expertise in iPSC manufacturing and engineering with BioLamina’s best-in-class cell culture matrices provides a complete and robust platform, reducing timelines and improving the probability of clinical success. We are excited to work together setting new standards for quality and efficiency in the industry,” said Benjamin Fryer, PhD, CEO of Pluristyx.
Therése Kallur, PhD, CSBDO of BioLamina, added, “At BioLamina, our focus has always been to provide researchers with biologically relevant and clinically robust culture environments. By combining our full-length laminin matrices with Pluristyx’s advanced iPSC technologies, we are enabling a seamless and defined workflow that meets the rigorous demands of clinical translation. This partnership allows us to support developers with solutions that not only improve consistency and scalability, but also bring the field of regenerative medicine closer to delivering safe and effective therapies to patients.”
BioLamina develops and manufactures laminin-based cell culture matrices for research and clinical applications. Their Biolaminin® substrates are chemically defined, animal origin-free, and designed to replicate the function of niche-specific proteins found in nature. The company is based in Stockholm, Sweden.
Pluristyx provides iPSC-based tools and technologies, including off-the-shelf iPSC lines, genetic engineering solutions, and support services aimed at streamlining the path from research to clinic. Their offerings include PluriKit™, PluriForm™ Organoids, and PluriBank™ polyclonal stem cells, incorporating features like FailSafe®, iACT™, and hypoimmune engineering.
For more information, visit BioLamina and Pluristyx.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
